🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you ACRO - American College of Radiation Oncology for an extremely informative and exciting meeting! Great people, education sessions, and presentations. #ACRO2025 is one for the books! And thank you Dr. Harris for a great discussion during my poster session!

"Deintensification of [chemoRT] treatments for HPV-associated oropharyngeal cancers is of very high interest to patients and researchers, but our study makes clear that these approaches should remain experimental.” - Sue Yom, MD, PhD, FASTRO ascopost.com/news/april-202… via The ASCO Post

📣 On the importance of specialty representation in committees for treatment recommendation and management of cancer 👏👏👏

📣Big shoutout to our faculty members Tufts Medical Center & BIDMC radiation onology residency, Dr. Jang and Dr. Huber, for being a speaker and moderator at this year's ASTRO Refresher Course! Thank you for all that you do for us and for the #radonc community

Excited to be presenting our research ASCO meeting this year! Can't wait to share our findings on patterns of immunotherapy use in different groups of stage 3 NSCLC patients who were treated definitively with chemoRT: meetings.asco.org/abstracts-pres… Tufts Medical Center Research BIDMC Cancer Center

Really helpful guide as I am learning to respond to reviewers, submitting my research to journals: sciencedirect.com/science/articl…

In the first advance in 20+ years for pts with locally advanced #HeadAndNeckCancer, a phase 3 clinical trial presented by Ravi Uppaluri, MDPhD at #AACR25 shows pembrolizumab before and after standard-of-care surgery significantly extends event-free survival. Robert Haddad Dana-Farber

Incredible findings of Phase II study where px with stage I, II, or III dMMR solid tumors that were amenable to curative-intent surgery were treated with neoaduvant dostarlimab for 6 months: ➡️ recurrence-free survival at 2 years was 92% #AACR25 #oncology #research

Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25

The most clinically relevant science in oncology will be presented at #ASCO25, and you can now view the full 5,000 abstracts & their presentation date, time & location info: brnw.ch/21wSRrE

Thank you ACRO - American College of Radiation Oncology for this publishing opportunity, through #CURiE ! I had the pleasure of presenting this unique case at #ACRO2025. And thank you to my coresidents, Raj and Alvin, for your help!

Thrilled to be at #ASCO25 ! Excited to witness and be a part of the forefront of cancer research! And honored to present research ASCO

Day 2 of #ASCO25! Exciting new frontiers in harnessing power of AI to better cancer care! As Dr. Robin Zon, President of ASCO, & Ms. Ruth Porat, President & CIO of Google and Alphabet, mentioned, AI is augmenting human capabilities, and it's about using it as an agent for change

#ASCO25 today: #TuftsMedicine @tuftsmcradonc's Chaewon Hwang, M.D. presents in Hall A - Posters, 9 AM to noon CT: How social determinants of health affect immunotherapy use in patients with stage III non-small cell lung cancer after chemoradiation. bit.ly/4mW2PRB

Effective 1 PM CT today, June 2, Dr. Eric Small will begin his term as Eric J. Small, MD, FASCO. Thank you, Dr. Zon, for your leadership over the past year! #ASCO25

🚨ESOPEC, Patterns of Recurrence🚨 🔥DM is the predominant pattern of recurrence and a large driver of mortality (~30-50%) ⚠️Locoregional Recurrence Remains notable (~20%) 🧐 Wonder about combined (Chemo + CRT) 🧨 to build on D-FLOT or FLOT, ❓ with organ preservation #ASCO25

We are grateful to our ~44,000 attendees who made #ASCO25 a success & the place to be! With nearly 40% joining us from outside the U.S., we are truly a global community united by our shared goal of improving #CancerCare & pt outcomes around the world. A heartfelt ‘thank you.’ 💗

Want to share practice-changing research from #ASCO25 with your patients? 18 summaries highlighting key studies in #BreastCancer, #ColorectalCancer, #LungCancer, and more are available NOW: brnw.ch/21wT8gd